Evidence map›Paper›PMID 32420384›Full record

Trial reportBioMed research international2020

Correlation between Skip N2 Metastases and SUV

Wang Jian, Peng Ming-Ya, Xu Long-Bao, Zhao Jun, Shao Guo-Qiang

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Wang JianOncology Center, Jiangyin People's Hospital, Affiliated Hospital of Southeast University, Jiangyin 214400, China.
Peng Ming-YaDepartment of Nuclear Medicine, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China.
Xu Long-BaoDepartment of Nuclear Medicine, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China.
Zhao JunDepartment of Nuclear Medicine, Changzhou Second People's Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China.ORCID https://orcid.org/0000-0003-0262-3394
Shao Guo-QiangDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing 210006, China.ORCID https://orcid.org/0000-0002-3277-6933
Changzhou No.2 People's Hospital · CNJiangyin People's Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe aim at investigating the correlation between skip N2 metastases (SN2) and SUV METHODS AND

resultsWe retrospectively analyzed the factors that might affect the pathogenesis of SN2 in these patients. The clinical SN2 symptoms in patients with squamous carcinoma or adenocarcinoma were investigated. The work curve was utilized to analyze the optimal cutoff value for the SUV

conclusionsThe differences of clinical features of the patients in the SN2 group and non-SN2 group in the NSCLC patients were associated with the pathological subtypes, which were featured by lower SUV

Indexed as

Carcinoma, Non-Small-Cell LungGene Expression Regulation, NeoplasticLung NeoplasmsPositron Emission Tomography Computed TomographyAgedFemaleFluorodeoxyglucose F18HumansKi-67 AntigenMaleMiddle AgedNeoplasm MetastasisFluorodeoxyglucose F18Ki-67 AntigenMKI67 protein, human

Identifiers

PMID32420384
PMCPMC7201773
OpenAlexW3018142612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.